| pubmed-article:20081878 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20081878 | lifeskim:mentions | umls-concept:C0018133 | lld:lifeskim |
| pubmed-article:20081878 | lifeskim:mentions | umls-concept:C0042866 | lld:lifeskim |
| pubmed-article:20081878 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:20081878 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:20081878 | pubmed:dateCreated | 2010-9-8 | lld:pubmed |
| pubmed-article:20081878 | pubmed:abstractText | GVHD remains a major source of morbidity and mortality after allogeneic BMT. GVHD is mediated by alloreactive T cells derived from the hematopoietic graft that target host tissues. Pre-clinical models have shown that presentation of alloantigens by host DCs results in the activation of donor-derived T cells that mediate GVHD. Strategies that interfere with the Ag-presenting capacity of DCs after allogeneic transplantation may decrease the risk of developing GVHD. Vitamin D is a hormone essential for calcium metabolism that shows immunomodulatory properties. We showed that correction of vitamin D deficiency appeared to mitigate manifestations of GVHD. In pre-clinical studies, we have shown that vitamin D inhibits DC maturation, polarizes T-cell populations toward the expression of Th2 as compared with Th1 cytokines, and blunts allogeneic T-cell proliferation in response to DC stimulation. Exposure to vitamin D resulted in increased expression of IDO, an enzyme responsible for tryptophan metabolism that is upregulated in tolerizing DCs. These data suggest that exposure to vitamin D results in immature DC populations that bias toward tolerizing rather than stimulatory T-cell populations. Vitamin D may therefore have a role in the prevention of GVHD. | lld:pubmed |
| pubmed-article:20081878 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20081878 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20081878 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20081878 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20081878 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20081878 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20081878 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20081878 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:20081878 | pubmed:issn | 1476-5365 | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:KufeDD | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:AhmadRR | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:LevineJ DJD | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:RosenblattJJ | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:MillsHH | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:StevensonKK | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:WuZZ | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:JoyceRR | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:BoussiotisVV | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:AviganDD | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:BissonnetteAA | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:VasirBB | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:TzachanisDD | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:ZarwanCC | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:KeefeWW | lld:pubmed |
| pubmed-article:20081878 | pubmed:author | pubmed-author:GlotzbeckerBB | lld:pubmed |
| pubmed-article:20081878 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20081878 | pubmed:volume | 45 | lld:pubmed |
| pubmed-article:20081878 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20081878 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20081878 | pubmed:pagination | 1463-8 | lld:pubmed |
| pubmed-article:20081878 | pubmed:meshHeading | pubmed-meshheading:20081878... | lld:pubmed |
| pubmed-article:20081878 | pubmed:meshHeading | pubmed-meshheading:20081878... | lld:pubmed |
| pubmed-article:20081878 | pubmed:meshHeading | pubmed-meshheading:20081878... | lld:pubmed |
| pubmed-article:20081878 | pubmed:meshHeading | pubmed-meshheading:20081878... | lld:pubmed |
| pubmed-article:20081878 | pubmed:meshHeading | pubmed-meshheading:20081878... | lld:pubmed |
| pubmed-article:20081878 | pubmed:meshHeading | pubmed-meshheading:20081878... | lld:pubmed |
| pubmed-article:20081878 | pubmed:meshHeading | pubmed-meshheading:20081878... | lld:pubmed |
| pubmed-article:20081878 | pubmed:meshHeading | pubmed-meshheading:20081878... | lld:pubmed |
| pubmed-article:20081878 | pubmed:meshHeading | pubmed-meshheading:20081878... | lld:pubmed |
| pubmed-article:20081878 | pubmed:meshHeading | pubmed-meshheading:20081878... | lld:pubmed |
| pubmed-article:20081878 | pubmed:meshHeading | pubmed-meshheading:20081878... | lld:pubmed |
| pubmed-article:20081878 | pubmed:meshHeading | pubmed-meshheading:20081878... | lld:pubmed |
| pubmed-article:20081878 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20081878 | pubmed:articleTitle | Immunomodulatory effects of vitamin D: implications for GVHD. | lld:pubmed |
| pubmed-article:20081878 | pubmed:affiliation | Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. jrosenb1@bidmc.harvard.edu | lld:pubmed |
| pubmed-article:20081878 | pubmed:publicationType | Journal Article | lld:pubmed |
